Sara J. Knight

Dr. Sara J. Knight


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Medical Care
Verified
Journal Article
Closed access
MSMichael A. Steinman
Michael A. Steinman
LDLiezel Dimaano
Liezel Dimaano
CPCarolyn A. Peterson
Carolyn A. Peterson
PHPaul Heidenreich
Paul Heidenreich
SKSara J. Knight
Sara J. Knight
PKPeter J. Kaboli
Peter J. Kaboli
Background: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems. Methods: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker. Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients. These reasons were classified using a published taxonomy. Results: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%–58% of patients and contextual reasons in 11%–17%. Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001). In these interviews, biomedical reasons for nonprescribing were cited in 50%–70% of patients, and contextual reasons in 64%–70%. The most common contextual reasons were comanagement with other clinicians (32%–35% of patients), patient preferences and nonadherence (15%–24%), and clinician belief that the medication is not indicated in the patient (12%–20%). Conclusions: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records. The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.

29 March 2022 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
SKSara J. Knight
Sara J. Knight
JHJeffrey P. Haibach
Jeffrey P. Haibach
AHAlison B. Hamilton
Alison B. Hamilton
JWJeff Whittle
Jeff Whittle
SOSarah S. Ono
Sarah S. Ono
SZSusan L. Zickmund
Susan L. Zickmund
With 20 million living veterans and millions more immediate family members, and approximately 9 million veterans enrolled in the nationally networked VA healthcare system, representing the interests and needs of veterans in this complex community is a substantial endeavor. Based on the importance of engaging Veterans in research, the VA Health Services Research and Development (HSR&D) Service convened a Working Group of VA researchers and Veterans to conduct a review of patient engagement models and develop recommendations for an approach to engage Veterans in health research that would incorporate their unique lived experiences and interests, and their perspectives on research priorities. The Working Group considered the specific context for Veteran engagement in research that includes other VA stakeholders from the operational and clinical leadership of the VA Health Administration (VHA). The resulting model identifies the range of potential stakeholders and three domains of relevant constructs—processes expected to facilitate Veteran engagement in research with other stakeholders, individual stakeholder and external factors, and outcomes. The expectation is that Veteran engagement will benefit research to policy and practice translation, including increasing the transparency of research and producing knowledge that is readily accepted and implemented in healthcare.

29 April 2004 in Health Expectations
Verified
Journal Article
Open access
PDF file
AEArthur S. Elstein
Arthur S. Elstein
GCGretchen B. Chapman
Gretchen B. Chapman
JCJoan S. Chmiel
Joan S. Chmiel
SKSara J. Knight
Sara J. Knight
CCCheeling Chan
Cheeling Chan
CBCharles L. Bennett
Charles L. Bennett
Purpose  To examine the agreement between prostate cancer patients’ utilities for selected health states and their rankings of the importance of six attributes of the health states and the clinicians’ judgements of what would be in the patients’ best interests.Method  Patients with newly diagnosed localized prostate cancer individually completed a time trade‐off utility assessment shortly after being diagnosed. The health states evaluated were constructed from a multi‐attribute utility model that incorporated six aspects of living with the disease and outcomes of treatment. Each patient assessed his current health state and three hypothetical states that might occur in the future, and provided rankings of the importance of the six attributes. The clinicians caring for each patient independently provided their views of what utilities and importance rankings would be in the patient's best interest.Results  The across‐participant correlations between patients’ and clinicians’ utilities were very low and not statistically significant. Across‐participant correlations between patient and clinician importance rankings for the six attributes were also low. Across‐health state and across‐attribute correlations between utilities or importance rankings were highly variable across patient–clinician pairs.Conclusion  In the clinical settings studied, there is not a strong relationship between valuations of current and possible future health states by patients with newly diagnosed prostate cancer and their clinicians. Implications of these results for substituted judgement, when clinicians advise their patients or recommend a treatment strategy, are discussed.

Verified
Journal Article
Open access
PDF file
ALAmy A. Lemke
Amy A. Lemke
MTMichelle Thompson
Michelle Thompson
EGEmily C. Gimpel
Emily C. Gimpel
KMKatelyn C. McNamara
Katelyn C. McNamara
CRCarla A. Rich
Carla A. Rich
KBKyle B. Brothers
Kyle B. Brothers
Background: It is critical to understand the wide-ranging clinical and non-clinical effects of genome sequencing (GS) for parents in the NICU context. We assessed parents’ experiences with GS as a first-line diagnostic tool for infants with suspected genetic conditions in the NICU. Methods: Parents of newborns (N = 62) suspected of having a genetic condition were recruited across five hospitals in the southeast United States as part of the SouthSeq study. Semi-structured interviews (N = 78) were conducted after parents received their child’s sequencing result (positive, negative, or variants of unknown significance). Thematic analysis was performed on all interviews. Results: Key themes included that (1) GS in infancy is important for reproductive decision making, preparing for the child’s future care, ending the diagnostic odyssey, and sharing results with care providers; (2) the timing of disclosure was acceptable for most parents, although many reported the NICU environment was overwhelming; and (3) parents deny that receiving GS results during infancy exacerbated parent–infant bonding, and reported variable impact on their feelings of guilt. Conclusion: Parents reported that GS during the neonatal period was useful because it provided a “backbone” for their child’s care. Parents did not consistently endorse negative impacts like interference with parent–infant bonding.

18 November 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SSStephanie L Shimada
Stephanie L Shimada
MZMark S Zocchi
Mark S Zocchi
THTimothy P Hogan
Timothy P Hogan
SKStefan G Kertesz
Stefan G Kertesz
ARArmando J Rotondi
Armando J Rotondi
THThomas K Houston
Thomas K Houston
Background: Although secure messaging (SM) between patients and clinical team members is a recommended component of continuous care, uptake by patients remains relatively low. We designed a multicomponent Supported Adoption Program (SAP) to increase SM adoption among patients using the Veterans Health Administration (VHA) for primary care. Objective: Our goals were to (1) conduct a multisite, randomized, encouragement design trial to test the effectiveness of an SAP designed to increase patient engagement with SM through VHA’s online patient portal (My HealtheVet [MHV]) and (2) evaluate the impact of the SAP and patient-level SM adoption on perceived provider autonomy support and communication. Patient-reported barriers to SM adoption were also assessed. Methods: We randomized 1195 patients at 3 VHA facilities who had MHV portal accounts but had never used SM. Half were randomized to receive the SAP, and half served as controls receiving usual care. The SAP consisted of encouragement to adopt SM via mailed educational materials, proactive SM sent to patients, and telephone-based motivational interviews. We examined differences in SM adoption rates between SAP recipients and controls at 9 months and 21 months. Follow-up telephone surveys were conducted to assess perceived provider autonomy support and self-report of telephone communication with clinical teams. Results: Patients randomized to the SAP had significantly higher rates of SM adoption than the control group (101/595, 17.0% vs 40/600, 6.7%; P<.001). Most adopters in the SAP sent their first message without a motivational interview (71/101, 70.3%). The 10-percentage point difference in adoption persisted a full year after the encouragement ended (23.7%, 142/600 in the SAP group vs 13.5%, 80/595 in the control group, P<.001). We obtained follow-up survey data from 49.54% (592/1195) of the participants. SAP participants reported higher perceived provider autonomy support (5.7 vs 5.4, P=.007) and less telephone use to communicate with their provider (68.8% vs 76.0%, P=.05), compared to patients in the control group. Patient-reported barriers to SM adoption included self-efficacy (eg, not comfortable using a computer, 24%), no perceived need for SM (22%), and difficulties with portal password or login (17%). Conclusions: The multicomponent SAP was successful in increasing use of SM 10 percentage points above standard care; new SM adopters reported improved perceptions of provider autonomy support and less use of the telephone to communicate with their providers. Still, despite the encouragement and technical assistance provided through the SAP, adoption rates were lower than anticipated, reaching only 24% at 21 months (10% above controls). Common barriers to adoption such as limited perceived need for SM may be more challenging to address and require different interventions than barriers related to patient self-efficacy or technical difficulties. Trial Registration: ClinicalTrials.gov NCT02665468; https://clinicaltrials.gov/ct2/show/NCT02665468

1 May 2014 in Urologic Clinics of North America
Verified
Journal Article
Closed access
SKSara J. Knight
Sara J. Knight